Intellia Therapeutics (NTLA) EBITDA Margin (2015 - 2026)
Intellia Therapeutics (NTLA) posted quarterly EBITDA Margin of 668.08% for Q1 2026, up 5850.0% year-over-year from 11.23% in Q1 2025, and down 55.78% quarter-over-quarter from 428.86% in Q4 2025.
Intellia Therapeutics (NTLA) EBITDA Margin (2015 - 2026) Analysis & Trends
Intellia Therapeutics (NTLA) has reported EBITDA Margin for 12 consecutive years, with 668.08% the latest figure, recorded in Q1 2026.
- In Q1 2026, EBITDA Margin rose 5850.0% year-over-year to 668.08%; the TTM figure through Mar 2026 stood at 636.56% (up 55080.0% YoY), while the FY2025 annual figure was 651.67%, up 27143.0% from the prior year.
- EBITDA Margin eased to 668.08% in Q1 2026 per NTLA's latest filing, from 428.86% in the prior quarter.
- Across five years, EBITDA Margin topped out at 7297.44% in Q4 2023 and bottomed at 1998.61% in Q2 2024.
- Historically, EBITDA Margin has averaged 452.5% across 5 years, with a median of 808.86% in 2025.
- Annual changes were most pronounced in 2023 — EBITDA Margin soared 810852 bps — and 2024, when it tumbled 835731 bps.
- Intellia Therapeutics' EBITDA Margin stood at 811.07% in 2022, then surged by 1000 bps to 7297.44% in 2023, then slumped by 115 bps to 1059.86% in 2024, then soared by 60 bps to 428.86% in 2025, then sank by 56 bps to 668.08% in 2026.
- Business Quant data shows NTLA's EBITDA Margin at 668.08% in Q1 2026, 428.86% in Q4 2025, and 808.86% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 37.40% |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 30.15% |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 31.68% |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 19.06% |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -77,569,866.34% |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 19.75% |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 17.93% |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -0.36% |
| 10 | Intellia Therapeutics | 1.67 Bn | 1.67 Bn | - | -1,472.25% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -1,472.25% |
| Mar 31, 2026 | -668.08% |
| Dec 31, 2025 | -428.86% |
| Sep 30, 2025 | -808.86% |
| Jun 30, 2025 | -772.17% |
| Mar 31, 2025 | -726.57% |
| Dec 31, 2024 | -1,059.86% |
| Sep 30, 2024 | -1,588.96% |
| Jun 30, 2024 | -1,998.61% |
| Mar 31, 2024 | -394.00% |
| Dec 31, 2023 | 7,297.44% |
| Sep 30, 2023 | -1,093.29% |
| Jun 30, 2023 | -973.47% |
| Mar 31, 2023 | -888.13% |
| Dec 31, 2022 | -811.07% |
| Sep 30, 2022 | -795.49% |
| Jun 30, 2022 | -700.65% |
| Mar 31, 2022 | -1,281.96% |
| Dec 31, 2021 | -625.60% |
| Sep 30, 2021 | -999.35% |